ART

• Post-102 • Prévalence d'Ambrosia Artemisiifolia en Italie: Analyse bioinformatique et aérobiologie botanique > A. Alessandro CINQUANTASEI (Bari) 09h00 • INT5 • Introduction Organizing Committee > L. Laurent REBER (Toulouse) 09h15 • INT6 • Session 1: impact of diet modification on allergy 09h15 • INT7 • Modelling immune pathways in allergen induced mucosal type 2 inflammation and modulatory effects of human milk oligosaccharides > L. Linette WILLEMSEN (Utrecht) 09h45 • INT8 • Dietary fermentable carbohydrates promote mucosal mast cell-dependent visceral hypersensitivity and type 2 immune responses > J. Jasper KAMPHUIS (Toulouse) 10h15 • INT9 • Dietary Transition and Allergenicity: Role of Novel Plant Proteins and Food Processing > W. Wieneke DIJK (Nantes) 10h45 • INT10 • Coffee break 11h05 • INT11 • Session 2: Integrative Diagnostics in Allergy 11h05 • INT12 • New advances in immune mechanisms and diagnosis of food allergy > A. Alexandra SANTOS (Londres) 11h35 • INT13 • From Open Databases to Predictive Algorithms: The Future of Allergy > J. Julien GORET (Bordeaux) 12h05 • INT14 • Early dietary exposome and atopic diseases > K. Karine ADEL-PATIENT (Gif-Sur-Yvette) 12h35 • INT15 • Lunch 13h45 • INT16 • Session 3: New insights into the mechanisms of allergy 13h45 • INT17 • Hormonal-mediated regulation of ILC2: towards a better understanding of sex differences in immunity > S. Sophie LAFFONT (Toulouse) 14h15 • INT18 • Prolonged IL-33 exposure differentially shapes connective and mucosal mast cell responses > L. Louise BATTUT (Toulouse) 14h35 • INT19 • How mast cells orchestrate and disrupt specialised immune niches in the lungs and beyond > R. Regis JOULIA (Londres) 15h05 • INT20 • Coffee break 15h25 • INT21 • Session 4: Impact of infections on asthma and allergy 15h25 • INT22 • The spectrum of lung neutrophils: from homeostasis to asthma exacerbations > C. Coraline RADERMECKER (Liège) 15h55 • INT23 • Consequences of microbial infections for allergic immune responses > P. Philipp STARKL (Vienne) 16h25 • INT24 • Closing lecture 16h25 • INT25 • Consequences of targeting Kit in humans – risks and benefits > M. Martin METZ (Berlin) 16h55 • INT26 • Concluding remarks > F. Frédéric BERARD (Lyon), V. Virginie DOYEN (Yvoir)